The University of Saskatchewan is starting a new clinical trial to slow the progression of the Alzheimer's disease. This trial will help develop NeuroEPO, a recombinant form of the naturally produced erythropoietin protein which prevents neuron cell death and promotes the growth and communication of neurons in the brain. Dr. Ron Geyer, Professor in the College of Medicine at the University of Saskatchewan and co-lead of the trail joins Gormley to explain the development of NeuroEPO and the impacts that trial can have in the fight against Alzheimer's.